lenacapavir
Gilead challenges ViiV in resistant HIV, filing twice-yearly therapy
Phil Taylor
Gilead Sciences, HIV, infectious disease, lenacapavir, Rukobia, ViiV Healthcare
0 Comment
X
Gilead challenges ViiV in resistant HIV, filing twice-yearly therapy
https://pharmaphorum.com/news/gilead-challenges-viiv-in-resistant-hiv-filing-twice-yearly-therapy/
Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavir
Phil Taylor
Gilead Sciences, HIV, infectious disease, lenacapavir, PrEP
0 Comment
X
Data sets up 2021 filings for Gilead’s twice-a-year HIV drug lenacapavir
https://pharmaphorum.com/news/data-sets-up-2021-filings-for-gileads-twice-a-year-hiv-drug-lenacapavir/